Natalya Risinskaya, Maria Gladysheva, Abdulpatakh Abdulpatakhov, Yulia Chabaeva, Valeriya Surimova, Olga Aleshina, Anna Yushkova, Olga Dubova, Nikolay Kapranov, Irina Galtseva, Sergey Kulikov, Tatiana Obukhova, Andrey Sudarikov, Elena Parovichnikova
The landscape of chromosomal aberrations in the tumor cells of the patients with B-ALL is diverse and can influence the outcome of the disease. Molecular karyotyping at the onset of the disease using chromosomal microarray (CMA) is advisable to identify additional molecular factors associated with the prognosis of the disease. Molecular karyotyping data for 36 patients with Ph-negative B-ALL who received therapy according to the ALL-2016 protocol are presented. We analyzed copy number alterations and their prognostic significance for CDKN2A / B , DMRTA , DOCK8 , TP53 , SMARCA2 , PAX5 , XPA , FOXE1 , HEMGN , USP45 , RUNX1 , NF1 , IGF2BP1 , ERG , TMPRSS2 , CRLF2 , FGFR3 , FLNB , IKZF1 , RUNX2 , ARID1B , CIP2A , PIK3CA , ATM , RB1 , BIRC3 , MYC , IKZF3 , ETV6 , ZNF384 , PTPRJ , CCL20 , PAX3 , MTCH2 , TCF3 , IKZF2 , BTG1 , BTG2 , RAG1 , RAG2 , ELK3 , SH2B3 , EP300 , MAP2K2 , EBI3 , MEF2D , MEF2C , CEBPA , and TBLXR1 genes, choosing t(4;11) and t(7;14) as reference events...
December 18, 2023: International Journal of Molecular Sciences